Zinc-L-Carnosine: The Gut Mucosal Protectant Used in Japanese Medicine for Decades

At a Glance

Zinc-L-carnosine (ZLC), sold as a prescription drug under the brand name Polaprezinc in Japan and South Korea since 1994, occupies a unique niche among gut-healing compounds. Unlike plain zinc supplements or L-carnosine taken separately, the chelated form behaves as a depot system: it adheres to inflamed mucosal surfaces, then slowly releases ionic zinc (Zn²⁺) and carnosine where the tissue is damaged. This local-release mechanism is why ZLC outperforms either constituent given alone in clinical trials — a finding that repeatedly surprised researchers who expected simple additivity.

Western medicine largely ignored ZLC until two parallel clinical pressures — NSAID-related gastrointestinal damage and chemotherapy-induced mucositis — drove renewed interest in the 2010s. Today, it appears in integrative oncology protocols, integrative gastroenterology programs, and functional medicine frameworks as a first-line gut-protective compound.

How Zinc-L-Carnosine Differs From Its Components

The chelation advantage

L-carnosine (beta-alanyl-L-histidine) has antioxidant and anti-glycation properties described separately in the carnosine literature. Zinc is an essential cofactor for over 300 enzymes, including those governing mucosal repair. When these two are co-chelated into ZLC, the resulting complex has a property neither possesses alone: mucosal bioadhesion.

ZLC binds to the mucus gel layer and to damaged epithelial cells via electrostatic and hydrophobic interactions. Once bound, it slowly hydrolyzes over 3–6 hours, releasing Zn²⁺ and carnosine at the injury site. Plasma levels of zinc after ZLC are modest and transient; the therapeutic action is local, not systemic. This explains why serum zinc does not reliably predict therapeutic response.

Why not take zinc + carnosine separately?

Studies directly comparing:

• ZLC vs. zinc alone
• ZLC vs. L-carnosine alone
• ZLC vs. zinc + L-carnosine (not chelated)

consistently show ZLC produces greater mucosal healing. The 2003 paper by Watari et al. in Journal of Gastroenterology demonstrated that ZLC reduced acetic acid–induced gastric ulcer area by 78%, while equimolar zinc or L-carnosine reduced it by only 29–44%. The chelate structure is not incidental — it is the therapeutic mechanism.

Clinical Evidence: What Does It Actually Do?

1. Gastric ulcer healing

ZLC was developed specifically as an anti-ulcer drug. The clinical evidence base is primarily Japanese, with over 20 randomized controlled trials and two large post-marketing surveillance studies involving more than 15,000 patients. Key findings:

• HELP trial (2001): ZLC 75 mg twice daily healed 81% of gastric ulcers at 8 weeks, compared to 72% with sucralfate (the then-standard).
• Mucosal healing was confirmed endoscopically, not just symptomatically.
• Tolerability was superior to sucralfate, with fewer constipation episodes.

The compound does not block acid (unlike PPIs); it accelerates mucosal repair and reduces the inflammatory signaling that perpetuates ulcer progression — a mechanistically different approach.

2. H. pylori eradication adjunct

H. pylori colonization depends partly on its ability to disrupt the gastric mucus layer. ZLC impairs H. pylori adhesion to gastric epithelium and reduces urease activity. When added to standard triple therapy (a PPI + two antibiotics), ZLC:

• Increased eradication rates by 7–12 percentage points in a 2014 meta-analysis of 8 trials.
• Reduced treatment-associated dyspepsia, which otherwise reduces adherence.
• Did not interfere with antibiotic bioavailability when taken at a different time.

For patients with antibiotic-resistant H. pylori strains or recurrent infection, ZLC is a reasonable adjunct rather than monotherapy.

3. NSAID-induced gastric damage

NSAIDs are the most common cause of non-H. pylori peptic ulcers. Standard prevention relies on PPIs, which have their own long-term risks (C. difficile susceptibility, hypomagnesemia, B12 malabsorption). ZLC offers an alternative or complement:

• A 2007 RCT showed ZLC reduced NSAID-induced gastric injury (scored by Lanza scale) comparably to omeprazole at 4 weeks.
• Mechanistically, ZLC preserves prostaglandin E2 synthesis in gastric mucosa — the pathway NSAIDs block — through a pathway independent of COX inhibition.
• For patients who need short-term NSAID courses (acute musculoskeletal injury, post-operative pain), ZLC is a rational co-prescription without the acid-rebound effect seen on PPI discontinuation.

4. Chemotherapy-induced oral mucositis

Oral mucositis — painful ulceration of the mouth and throat — affects 20–40% of patients receiving chemotherapy and up to 80% of those receiving head-and-neck radiation. It is a dose-limiting toxicity that leads to treatment interruptions, hospital admissions, and significant quality-of-life impairment.

ZLC reduces oral mucositis severity through the same bioadhesion and anti-inflammatory mechanisms that protect gastric mucosa. A 2017 Cochrane-registered systematic review and multiple subsequent RCTs support:

• Reduction in mucositis grade (WHO scale) by approximately 1 grade when used as a mouth rinse or oral supplement.
• Faster resolution of existing mucositis.
• Meaningful reduction in opioid analgesic requirements.

Protocols typically use 75 mg dissolved in water as a swish-and-swallow 2–3 times daily, starting 3 days before chemotherapy.

5. Leaky gut and intestinal permeability

ZLC has shown efficacy in animal and ex vivo models of intestinal barrier dysfunction. Mechanistically, it upregulates tight junction proteins (occludin, claudin-1, ZO-1) in intestinal epithelial cells. Human data remains limited to two open-label studies in irritable bowel syndrome and one in inflammatory bowel disease (IBD), but the mechanistic rationale is strong. This application is currently extrapolated from gastric evidence rather than supported by its own RCT base.

Dosing and Protocol

Standard dosage

• Gastric ulcer / NSAID protection: 75 mg ZLC twice daily with meals for 4–8 weeks
• H. pylori adjunct: Same dose, concurrent with the full antibiotic course
• Chemotherapy mucositis prevention: 75 mg twice daily starting 3 days pre-chemotherapy, continued through treatment
• Maintenance / gut-healing protocol: 37.5–75 mg once daily (lower end for long-term use)

Timing

ZLC is best taken with food or 30 minutes before meals. The mucosal adhesion is not impaired by food, and co-administration with meals reduces the rare nausea reported by some patients.

Duration

Clinical trials typically ran 4–8 weeks for ulcer healing. For maintenance gut health or as an NSAID co-prescription, continuous use appears safe based on the Japanese long-term safety database.

Zinc load

75 mg of ZLC provides approximately 16–17 mg of elemental zinc. At the standard 150 mg/day dose, that is 32–34 mg elemental zinc — just above the RDA of 11 mg (men) / 8 mg (women) but well below the tolerable upper limit of 40 mg/day. Clinically relevant zinc excess is unlikely at standard doses.

Drug Interactions and Contraindications

Fluoroquinolone antibiotics

ZLC chelates to fluoroquinolones (ciprofloxacin, levofloxacin, norfloxacin) and reduces their oral bioavailability by 30–50%. Separate by at least 2 hours; take the antibiotic first.

Tetracyclines

Similar chelation risk. Same 2-hour separation rule applies.

Copper

Long-term zinc supplementation at any source can deplete copper via metallothionein competition. If ZLC is used continuously for more than 3 months, monitoring serum copper and ceruloplasmin is prudent, and low-dose copper (1–2 mg/day) may be appropriate.

PPI co-administration

ZLC and PPIs work through entirely different mechanisms and can be used together. There is no pharmacokinetic interaction. The clinical question is whether both are necessary — often ZLC alone is sufficient for mild-to-moderate NSAID-related injury.

Contraindications

• Known hypersensitivity to zinc or L-carnosine (rare)
• Severe renal impairment (CKD stage 4–5): zinc accumulation risk; use with monitoring or avoid
• Wilson’s disease: copper-zinc competition could worsen copper excess

Practical Notes for Clinicians

Sourcing matters. The pharmaceutical product (Polaprezinc) contains 75 mg ZLC (equivalent to 16 mg zinc + 56 mg L-carnosine). Supplement market products vary in ZLC percentage and may contain additional ingredients. Recommend products that specify ZLC (polaprezinc) content rather than just “zinc carnosine blend.”

Stool color. A small proportion of patients report slight darkening of stool with ZLC, a benign consequence of unabsorbed zinc. It does not indicate gastrointestinal bleeding and resolves on dose reduction.

Children. Pediatric dosing data exists only for mucositis prevention in pediatric oncology (typically weight-based at 1–2 mg/kg/day ZLC). General gut-health use in children should proceed cautiously and under supervision.

Athletes on NSAIDs. A common use case is the competitive athlete taking daily NSAIDs for pain management during training blocks. ZLC 75 mg twice daily with the NSAID is a rational short-course protection strategy that avoids long-term PPI use and its rebound acid hypersecretion on discontinuation.

Related Articles

• Carnosine: The Anti-Glycation Dipeptide That Declines With Age — L-carnosine’s separate mechanisms for brain and anti-aging applications
• L-Glutamine for Gut Healing: Dosage, Timing, and Clinical Evidence — complementary mucosal repair support
• Zinc for Immune Function: Forms, Dosing, and What the Evidence Actually Shows — systemic zinc supplementation for immunity
• Protocols: Gut Reset Protocol — comprehensive gut healing framework where ZLC fits
• Butyrate Guide: Short-Chain Fatty Acids for Gut Lining Repair — synergistic gut-barrier compound